Vermeulen Françoise, Verscheure Virginie, Damis Eliane, Vermeylen Danièle, Leloux Gaëlle, Dirix Violette, Locht Camille, Mascart Françoise
Pediatric Department, Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
Clin Vaccine Immunol. 2010 Feb;17(2):258-62. doi: 10.1128/CVI.00328-09. Epub 2009 Dec 16.
Based on studies reporting specific antibody titers, it is recommended to vaccinate preterm infants against Bordetella pertussis according to their chronological age. However, as specific T-cell responses also are involved in the protection against B. pertussis, we have determined whether highly preterm infants (<31 weeks) are able to mount these immune responses during vaccination. Forty-eight premature infants were vaccinated at 2, 3, and 4 months of their chronological age with an acellular (Pa; n = 24) or a whole-cell (Pw; n = 24) tetravalent diphtheria-tetanus-pertussis-polio vaccine, and blood samples were collected at 2, 3, and 6 months of age. Most of the Pa- and Pw-vaccinated infants developed at 3 or 6 months of age a gamma interferon (IFN-gamma) response to the B. pertussis antigens, accompanied by an interleukin-5 (IL-5) and IL-13 secretion for the Pa-vaccinated infants. No association was found between a very low infant birth weight, the occurrence of severe infections, and corticosteroid treatment or the administration of gammaglobulins with a low level of antigen-induced IFN-gamma secretion. We conclude that like full-term infants, most preterm infants are able to mount a specific cellular immune response to the administration of the first doses of an acellular or a whole-cell pertussis vaccine.
根据报告特定抗体滴度的研究,建议按照实际年龄为早产儿接种百日咳博德特氏菌疫苗。然而,由于特异性T细胞反应也参与了针对百日咳博德特氏菌的保护作用,我们确定了极早产儿(<31周)在接种疫苗期间是否能够产生这些免疫反应。48名早产儿在其实际年龄的2、3和4个月时接种了无细胞(Pa;n = 24)或全细胞(Pw;n = 24)四价白喉-破伤风-百日咳-脊髓灰质炎疫苗,并在2、3和6个月大时采集血样。大多数接种Pa和Pw疫苗的婴儿在3或6个月大时对百日咳博德特氏菌抗原产生了γ干扰素(IFN-γ)反应,接种Pa疫苗的婴儿还伴有白细胞介素-5(IL-5)和IL-13分泌。极低出生体重、严重感染的发生、皮质类固醇治疗或γ球蛋白的使用与低水平抗原诱导的IFN-γ分泌之间未发现关联。我们得出结论,与足月儿一样,大多数早产儿在接种第一剂无细胞或全细胞百日咳疫苗后能够产生特异性细胞免疫反应。